A new study, recently published by Prof. Pierre Laurent-Puig’s team in the European Journal of Cancer, introduces a tool to help optimize treatment strategies for patients with metastatic dMMR/MSI-H colorectal cancer.
By combining the analysis of an 8-gene signature with specific tumor characteristics, researchers are able to identify patients who are most likely to benefit from combined immunotherapy (anti-PD-1 + anti-CTLA-4).
Discover the key findings of this study in our video. (Content generated using NotebookLM and reviewed by CARPEM teams.)
Reference:
From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer Ambrosini M et al., European Journal of Cancer, 2026